ONCORUS

oncorus-logo

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

#People #Financial #Event #Website #More

ONCORUS

Social Links:

Industry:
Biotechnology Medical Therapeutics

Founded:
2015-04-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.oncorus.com

Total Employee:
11+

Status:
Active

Contact:
(857)320-6402

Email Addresses:
[email protected]

Total Funding:
218.49 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics



Current Advisors List

luke-evnin_image

Luke Evnin Board Of Director @ Oncorus
Board_member

Current Employees Featured

lorena-lerner_image

Lorena Lerner
Lorena Lerner Vice President Research @ Oncorus
Vice President Research
2019-01-01

theodore-t-ashburn_image

Theodore T. Ashburn
Theodore T. Ashburn President & CEO @ Oncorus
President & CEO
2018-07-01

john-mccabe_image

John McCabe
John McCabe Chief Financial Officer @ Oncorus
Chief Financial Officer
2017-10-01

kenneth-greenberg_image

Kenneth Greenberg
Kenneth Greenberg Co-Founder @ Oncorus
Co-Founder
2015-04-01

not_available_image

Steve Harbin
Steve Harbin COO and Chief of Staff @ Oncorus
COO and Chief of Staff

scott-a-canute_image

Scott A. Canute
Scott A. Canute Director @ Oncorus
Director
2020-12-01

john-goldberg_image

John Goldberg
John Goldberg Chief Medical Officer @ Oncorus
Chief Medical Officer
2022-02-01

Founder


cyrus-mozayeni_image

Cyrus Mozayeni

kenneth-greenberg_image

Kenneth Greenberg

mitchell-finer_image

Mitchell Finer

Stock Details


Company's stock symbol is NASDAQ:ONCR

Investors List

k2-healthventures_image

K2 HealthVentures

K2 HealthVentures investment in Post-IPO Debt - Oncorus

arkin-bio-ventures_image

Arkin Bio Ventures

Arkin Bio Ventures investment in Series B - Oncorus

cowen-healthcare-investments_image

Cowen Healthcare Investments

Cowen Healthcare Investments investment in Series B - Oncorus

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series B - Oncorus

celgene_image

Celgene

Celgene investment in Series B - Oncorus

deerfield_image

Deerfield

Deerfield investment in Series B - Oncorus

sphera-funds-management_image

Sphera Funds Management

Sphera Funds Management investment in Series B - Oncorus

shinhan-private-equity_image

Shinhan Private Equity

Shinhan Private Equity investment in Series B - Oncorus

sv-investment-partners_image

SV Investment Partners

SV Investment Partners investment in Series B - Oncorus

utc-investment-co_image

UTC Investment Co.

UTC Investment Co. investment in Series B - Oncorus

Official Site Inspections

http://www.oncorus.com

Unable to get host informations!!!

Loading ...

More informations about "Oncorus"

Oncorus - Crunchbase Company Profile & Funding

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. โ€ฆSee details»

Oncorus Inc (ONCR) Profile - The Globe and Mail

See the company profile for Oncorus Inc (ONCR) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»

Oncorus Company Profile | Management and Employees List

Oncorus headquarters are located in 50 Hampshire St Ste 401, Cambridge, Massachusetts, 02139, United States What are Oncorusโ€™s primary industries? Oncorusโ€™s main industries are: โ€ฆSee details»

Oncorus - LinkedIn

Oncorus is focused on realizing the full promise of IV-administered, self-amplifying RNA medicines to transform outcomes for cancer patients. We believe this modality has the โ€ฆSee details»

Oncorus Company Profile - Office Locations, Competitors ... - Craft

May 10, 2022 Oncorus is a biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. Using its two platforms, the โ€ฆSee details»

Oncorus, Inc. Company Profile | Andover, MA - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Oncorus, Inc. of Andover, MA. Get the latest business insights from Dun & Bradstreet.See details»

Working At Oncorus: Company Overview and Culture - Zippia

Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing โ€ฆSee details»

Oncorus - Overview, News & Similar companies | ZoomInfo.com

Jun 2, 2023 Oncorus Announces Workforce Reduction Plan ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company โ€ฆSee details»

Oncorus - Contacts, Employees, Board Members, Advisors & Alumni

Organization. Oncorus . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 6. Number of Board โ€ฆSee details»

Oncorus - Funding, Financials, Valuation & Investors - Crunchbase

Oncorus is registered under the ticker NASDAQ:ONCR . Their stock opened with $15.00 in its Oct 1, 2020 IPO. Oncorus is funded by 19 investors. K2 HealthVentures and Arkin Bio Ventures โ€ฆSee details»

Oncorus Company Profile 2024: Stock Performance & Earnings

Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company โ€ฆSee details»

Oncorus Inc (ONCR) Stock Price and News - The Globe and Mail

Real-time Price Updates for Oncorus Inc (ONCR), along with buy or sell indicators, analysis, charts, historical performance, news and moreSee details»

Governance Oncorus, Inc. - MarketScreener.com

Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The โ€ฆSee details»

Oncorus Announces Workforce Reduction Plan - Yahoo Finance

ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying โ€ฆSee details»

Oncorus - workinbiotech.com

Oncorus is generating next-generation immunotherapies to activate the immune system to target and destroy cancer cells. Oncorusโ€™ approach differs from current therapies that activate not โ€ฆSee details»

Oncorus liquidates a week after shedding workforce - Fierce Biotech

Jun 12, 2023 A week after Oncorus shed pretty much all its staff, the biotechโ€™s board has decided that the game is up and moved to liquidate the RNA-focused company. | A week after โ€ฆSee details»

Facing bankruptcy, Oncorus lays off 'substantially' all staff

Jun 2, 2023 Oncorus was already predicting that the $45 million in cash and equivalents it ended March with would only last until the third quarter of the year. Oncorus is far from the only โ€ฆSee details»

Oncorus - Crunchbase

Oncorus, Avstera Therapeutics, Vor Biopharma, Enliven Therapeutics, Interius BioTherapeutics, and Pinpoint Therapeutics are all involved in the oncology and biotech sector. Avstera โ€ฆSee details»

Oncorus to Present Initial Data from its Ongoing Phase 1 Clinical โ€ฆ

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for โ€ฆSee details»

Oncorus Announces Portfolio Reprioritization to Focus on

Nov 30, 2022 Company now focused on the development of ONCR-021, Oncorusโ€™ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains โ€ฆSee details»

linkstock.net © 2022. All rights reserved